These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 6258262)

  • 1. A biphasic effect of prostacyclin (PGI2) on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Thromb Res; 1980 Sep; 19(6):877-81. PubMed ID: 6258262
    [No Abstract]   [Full Text] [Related]  

  • 2. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Pharmacol Res Commun; 1979 Jul; 11(7):605-15. PubMed ID: 388470
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR
    Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
    [No Abstract]   [Full Text] [Related]  

  • 5. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
    Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
    Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
    Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of PGI2 on platelet aggregation induced by various stimulants.
    Ohtsu A; Hoshina K; Kurozumi S; Hashimoto Y; Noguchi T; Nicolaou KC
    Nihon Ketsueki Gakkai Zasshi; 1979 Aug; 42(4):659-66. PubMed ID: 388963
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
    Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
    Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
    Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of platelet activation by plasmin and prostaglandin I2.
    Schafer AI; Zavoico GB; Loscalzo J; Maas AK
    Blood; 1987 May; 69(5):1504-7. PubMed ID: 3032310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prostacyclin, 6-keto-PGF1 alpha PGF2 alpha and 15[S]15-methyl-PGF2 alpha on platelet aggregation in vitro.
    Marmo E; Somma A; Ottavo R; Vairo G; Spaziante G; DiMezza F; Paone G
    J Med; 1981; 12(2-3):97-108. PubMed ID: 7024451
    [No Abstract]   [Full Text] [Related]  

  • 16. Biology and therapeutic potential of prostacyclin.
    Moncada S
    Stroke; 1983; 14(2):157-68. PubMed ID: 6301111
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostaglandins and platelet aggregation.
    Smith JB
    Acta Med Scand Suppl; 1981; 651():91-9. PubMed ID: 7034481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.
    Moncada S; Vane JR
    Pharmacol Rev; 1978 Sep; 30(3):293-331. PubMed ID: 116251
    [No Abstract]   [Full Text] [Related]  

  • 20. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.